Promising new cocktail aims to boost survival in rare throat cancer
NCT ID NCT05305131
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study tests whether adding two extra drugs (pembrolizumab and bevacizumab) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer. About 50 adults with stage III or IVA disease will receive either standard chemo or the four-drug combo. The goal is to see if the new mix leads to better tumor shrinkage and longer survival, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.